Freenome

NASDAQ: FRNM

London · Founded 2015 · United Kingdom corporation · 15 known investors

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.

AI & Machine LearningBiotechDigital HealthHealthtechMedical Devicesin /freenome

Founders & leadership

Riley EnnisCo-Founder and Chief Product Officer

Stuart LawsonDirector

Charles RobertsDirector

Gabriel OtteDirector

Investors · 15

RA Capital✓ verifiedBoston

AME Cloud VenturesPalo Alto · $1M – $10M

Andreessen HorowitzMenlo Park · $500K – $50M

Artis VenturesSan Francisco · $50K – $25M

Asset Management CompanyPalo Alto · $500K – $2M

Averin CapitalNew York

Bain Capital Life SciencesBoston

Catalio Capital Management, LPNew York

CRV (Charles River Ventures)Bay Area · $250K – $5M

DCVC (Data Collective)Palo Alto · $5M – $25M

EcoR1 CapitalSan Francisco

GV (Google Ventures)Mountain View · $250K – $50M

Kaiser Permanente VenturesSan Francisco · $2M – $5M

Roche Venture FundBasel · $648K – $3.2M

Agent CapitalreportedWaltham

Reported raises · per SEC filings

Form D private placements

▶$800KraisedOct 2015 · 4 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Stuart LawsonDirector
Charles RobertsDirector
Gabriel OtteDirector

Offering amount: $800K
Amount sold: $800K
First sale: Oct 2015
Incorporated: Corporation, United Kingdom, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.